Rezultati
eNauka >
Rezultati >
Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial
| Naziv: | Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial | Autori  : | Zamagni, Elena; ...; Bila, Jelena S.   ; ...; (broj koautora 53) |
Godina: | 2024 | Publikacija: | Blood (66th Annual Meeting of the American Society of Hematology (ASH), Dec 07-10, 2024) | ISSN: | 0006-4971 Blood Pretraži identifikator |
Izdavač: | [New York] : Elsevier | Tip rezultata: | Konferencijski rad | Kolacija: | vol. 144 br. Suppl 1 str. 494-494 | DOI: | 10.1182/blood-2024-205608 | WoS-ID: | 001415654100044 | URI: | https://enauka.gov.rs/handle/123456789/985048 | URL: | https://ashpublications.org/blood/article/144/Supplement%201/494/530315/Phase-3-Study-of-Teclistamab-Tec-in-Combination | Izvor metapodataka: | (Preuzeto iz Nasi u WoS) | M-kategorija: | Mp kategorija će biti prikazana naknadno. |
Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.